{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:55:54Z","timestamp":1794642954038,"version":"4.9.1"},"reference-count":155,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), a leading cause of chronic liver disease, has increased worldwide along with the epidemics of obesity and related dysmetabolic conditions characterized by impaired glucose metabolism and insulin signaling, such as type 2 diabetes mellitus (T2D). MASLD can be defined as an excessive accumulation of lipid droplets in hepatocytes that occurs when the hepatic lipid metabolism is totally surpassed. This metabolic lipid inflexibility constitutes a central node in the pathogenesis of MASLD and is frequently linked to the overproduction of lipotoxic species, increased cellular stress, and mitochondrial dysfunction. A compelling body of evidence suggests that the accumulation of lipid species derived from sphingolipid metabolism, such as ceramides, contributes significantly to the structural and functional tissue damage observed in more severe grades of MASLD by triggering inflammatory and fibrogenic mechanisms. In this context, MASLD can further progress to metabolic dysfunction-associated steatohepatitis (MASH), which represents the advanced form of MASLD, and hepatic fibrosis. In this review, we discuss the role of sphingolipid species as drivers of MASH and the mechanisms involved in the disease. In addition, given the absence of approved therapies and the limited options for treating MASH, we discuss the feasibility of therapeutic strategies to protect against MASH and other severe manifestations by modulating sphingolipid metabolism.<\/jats:p>","DOI":"10.3389\/fendo.2024.1400961","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T01:14:46Z","timestamp":1718759686000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis"],"prefix":"10.3389","volume":"15","author":[{"given":"Bruno","family":"Ramos-Molina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Rossell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"P\u00e9rez-Montes de Oca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Pardina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idoia","family":"Genua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina I.","family":"Rojo-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Juli\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Julve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didac","family":"Mauricio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000706","article-title":"From NAFLD to MASLD: Promise and pitfalls of a new definition\u2020","volume":"79","author":"Cusi","year":"2024","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.07.033","article-title":"Disease state transition probabilities across the spectrum of NAFLD: A systematic review and meta-analysis of paired biopsy or imaging studies","volume":"21","author":"Le","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi0759","article-title":"Found in translation\u2014Fibrosis in metabolic dysfunction\u2013associated steatohepatitis (MASH)","volume":"15","author":"Wang","year":"2023","journal-title":"Sci Transl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.11.005","article-title":"Long-term follow-up of patients with nonalcoholic fatty liver","volume":"7","author":"Rafiq","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3390\/metabo13111115","article-title":"Advances in noninvasive biomarkers for nonalcoholic fatty liver disease","volume":"13","author":"G\u00eelc\u0103-Blanariu","year":"2023","journal-title":"Metabolites"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181bcd6dd","article-title":"Assessment of hepatic steatosis by expert pathologists","volume":"250","author":"El-Badry","year":"2009","journal-title":"Ann Surg"},{"key":"B12","doi-asserted-by":"publisher","first-page":"113869","DOI":"10.1016\/j.addr.2021.113869","article-title":"Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis","volume":"176","author":"Kumar","year":"2021","journal-title":"Adv Drug Delivery Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"101143","DOI":"10.1016\/j.molmet.2020.101143","article-title":"Metabolic drivers of non-alcoholic fatty liver disease","volume":"50","author":"Bence","year":"2021","journal-title":"Mol Metab"},{"key":"B14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12072-020-10121-2","article-title":"How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease","volume":"15","author":"Geng","year":"2021","journal-title":"Hepatol Int"},{"key":"B15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.freeradbiomed.2019.05.029","article-title":"Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease","volume":"144","author":"Svegliati-Baroni","year":"2019","journal-title":"Free Radic Biol Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/metabo14010012","article-title":"Lipid metabolism in metabolic-associated steatotic liver disease (MASLD)","volume":"14","author":"Syed-Abdul","year":"2023","journal-title":"Metabolites"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2015.07.006","article-title":"Ceramides \u2013 lipotoxic inducers of metabolic disorders","volume":"26","author":"Chaurasia","year":"2015","journal-title":"Trends Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.3390\/ijms22115793","article-title":"A comprehensive review: sphingolipid metabolism and implications of disruption in sphingolipid homeostasis","volume":"22","author":"Quinville","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1042\/bj3350465","article-title":"Signal transduction of stress via ceramide","volume":"335","author":"Mathias","year":"1998","journal-title":"Biochem J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.78525","article-title":"Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease","volume":"19","author":"Zhu","year":"2023","journal-title":"Int J Biol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R800012-JLR200","article-title":"Thematic Review Series: Sphingolipids. Biodiversity of sphingoid bases (\u201csphingosines\u201d) and related amino alcohols","volume":"49","author":"Pruett","year":"2008","journal-title":"J Lipid Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-018-0046-6","article-title":"Author Correction: Sphingolipids and their metabolism in physiology and disease","volume":"19","author":"Hannun","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B23","article-title":"A treatise on the chemical constitution of the brain: based throughout upon original researches","volume":"22","author":"Thudichum","year":"1884","journal-title":"Glasgow Med J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0021-9258(17)35063-9","article-title":"Biochemistry of the sphingolipides; preparation of sphingolipides from beef brain and spinal cord","volume":"169","author":"Carter","year":"1947","journal-title":"J Biol Chem"},{"key":"B25","doi-asserted-by":"publisher","first-page":"109958","DOI":"10.1016\/j.cellsig.2021.109958","article-title":"Ceramide synthases: Reflections on the impact of Dr. Lina M. Obeid","volume":"82","author":"Kim","year":"2021","journal-title":"Cell Signal"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4419-6741-1_1","article-title":"An overview of sphingolipid metabolism: from synthesis to breakdown","volume":"688","author":"Gault","year":"2010","journal-title":"Adv Exp Med Biol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2018.12.013","article-title":"1-deoxysphingolipids","volume":"1864","author":"Lone","year":"2019","journal-title":"Biochim Biophys Acta (BBA) - Mol Cell Biol Lipids"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R111.254359","article-title":"Many ceramides","volume":"286","author":"Hannun","year":"2011","journal-title":"J Biol Chem"},{"key":"B29","doi-asserted-by":"publisher","first-page":"151337","DOI":"10.1016\/j.ejcb.2023.151337","article-title":"Ceramides and ceramide synthases in cancer: Focus on apoptosis and autophagy","volume":"102","author":"Alizadeh","year":"2023","journal-title":"Eur J Cell Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.05.078","article-title":"Non-alcoholic fatty liver disease: Insights from sphingolipidomics","volume":"504","author":"Montefusco","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbior.2016.10.002","article-title":"Ceramidases, roles in sphingolipid metabolism and in health and disease","volume":"63","author":"Coant","year":"2017","journal-title":"Adv Biol Regul"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/febs.12559","article-title":"Glycosphingolipids: synthesis and functions","volume":"280","author":"D\u2019Angelo","year":"2013","journal-title":"FEBS J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/iub.83","article-title":"Two sphingolipid transfer proteins, CERT and FAPP2: Their roles in sphingolipid metabolism","volume":"60","author":"Yamaji","year":"2008","journal-title":"IUBMB Life"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nature06097","article-title":"Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide","volume":"449","author":"D\u2019Angelo","year":"2007","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nature12423","article-title":"Vesicular and non-vesicular transport feed distinct glycosylation pathways in the Golgi","volume":"501","author":"D\u2019Angelo","year":"2013","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M201535200","article-title":"Ceramide kinase, a novel lipid kinase","volume":"277","author":"Sugiura","year":"2002","journal-title":"J Biol Chem"},{"key":"B37","doi-asserted-by":"publisher","first-page":"115427","DOI":"10.1016\/j.jep.2022.115427","article-title":"Danhe granule ameliorates nonalcoholic steatohepatitis and fibrosis in rats by inhibiting ceramide de novo synthesis related to CerS6 and CerK","volume":"295","author":"Zhu","year":"2022","journal-title":"J Ethnopharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.02.010","article-title":"Ceramide is metabolized to acylceramide and stored in lipid droplets","volume":"25","author":"Senkal","year":"2017","journal-title":"Cell Metab"},{"key":"B39","doi-asserted-by":"publisher","first-page":"158741","DOI":"10.1016\/j.bbalip.2020.158741","article-title":"Endogenous levels of 1-O-acylceramides increase upon acidic ceramidase deficiency and decrease due to loss of Dgat1 in a tissue-dependent manner","volume":"1865","author":"Bayerle","year":"2020","journal-title":"Biochim Biophys Acta (BBA) - Mol Cell Biol Lipids"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s43188-023-00193-1","article-title":"Integrative roles of sphingosine kinase in liver pathophysiology","volume":"39","author":"Kim","year":"2023","journal-title":"Toxicol Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002156","article-title":"Bile acids and sphingolipids in non-alcoholic fatty liver disease","volume":"135","author":"Jackson","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.S091181","article-title":"Fifty years of lyase and a moment of truth: sphingosine phosphate lyase from discovery to disease","volume":"60","author":"Saba","year":"2019","journal-title":"J Lipid Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-106336","article-title":"Ceramide induces p38 MAPK and JNK activation through a mechanism involving a thioredoxin-interacting protein-mediated pathway","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41419-019-2214-9","article-title":"Targeting alkaline ceramidase 3 alleviates the severity of nonalcoholic steatohepatitis by reducing oxidative stress","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.cell.2019.05.008","article-title":"CerS6-derived sphingolipids interact with mff and promote mitochondrial fragmentation in obesity","volume":"177","author":"Hammerschmidt","year":"2019","journal-title":"Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-1948-3","article-title":"Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat","volume":"48","author":"Stefan","year":"2005","journal-title":"Diabetologia"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2017.01.002","article-title":"Inducible overexpression of adiponectin receptors highlight the roles of adiponectin-induced ceramidase signaling in lipid and glucose homeostasis","volume":"6","author":"Holland","year":"2017","journal-title":"Mol Metab"},{"key":"B48","doi-asserted-by":"publisher","first-page":"115157","DOI":"10.1016\/j.bcp.2022.115157","article-title":"Ceramide de novo synthesis in non-alcoholic fatty liver disease: Pathogenic mechanisms and therapeutic perspectives","volume":"202","author":"Yu","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1172\/JCI43378","article-title":"Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid\u2013induced ceramide biosynthesis in mice","volume":"121","author":"Holland","year":"2011","journal-title":"J Clin Invest"},{"key":"B50","doi-asserted-by":"publisher","first-page":"100298","DOI":"10.1016\/j.jlr.2022.100298","article-title":"Endothelial acid sphingomyelinase promotes NLRP3 inflammasome and neointima formation during hypercholesterolemia","volume":"63","author":"Yuan","year":"2022","journal-title":"J Lipid Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.3390\/ijms20133328","article-title":"The NLRP3 inflammasome: an overview of mechanisms of activation and regulation","volume":"20","author":"Kelley","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M063511","article-title":"SphK1 mediates hepatic inflammation in a mouse model of NASH induced by high saturated fat feeding and initiates proinflammatory signaling in hepatocytes","volume":"56","author":"Geng","year":"2015","journal-title":"J Lipid Res"},{"key":"B53","article-title":"Role of Neutral Sphingomyelinases in Aging and Inflammation","volume-title":"Lipids in Health and Disease","author":"Nikolova-Karakashian","year":"2018"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/ijms21010040","article-title":"Sphingolipids in non-alcoholic fatty liver disease and hepatocellular carcinoma: ceramide turnover","volume":"21","author":"Simon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B56","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/jcm10040792","article-title":"Roles of ceramides in non-alcoholic fatty liver disease","volume":"10","author":"Hajduch","year":"2021","journal-title":"J Clin Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"11380","DOI":"10.3390\/ijms231911380","article-title":"Molecular advances in MAFLD\u2014A link between sphingolipids and extracellular matrix in development and progression to fibrosis","volume":"23","author":"Ko\u0142akowski","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00492.2015","article-title":"Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity","volume":"310","author":"Patterson","year":"2016","journal-title":"Am J Physiology-Endocrinology Metab"},{"key":"B59","article-title":"A lipidomic readout of disease progression in A diet-induced mouse model of nonalcoholic fatty liver disease","volume":"126","author":"Sanyal","year":"2015","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2012.04.005","article-title":"Role of ceramides in nonalcoholic fatty liver disease","volume":"23","author":"Pagadala","year":"2012","journal-title":"Trends Endocrinol Metab"},{"key":"B61","doi-asserted-by":"publisher","first-page":"16810","DOI":"10.1038\/s41598-019-53346-4","article-title":"Multi-technique comparison of atherogenic and MCD NASH models highlights changes in sphingolipid metabolism","volume":"9","author":"Montandon","year":"2019","journal-title":"Sci Rep"},{"key":"B62","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12944\u2013020-01425\u20131","article-title":"Hepatic lipid profile in mice fed a choline-deficient, low-methionine diet resembles human non-alcoholic fatty liver disease","volume":"19","author":"Haberl","year":"2020","journal-title":"Lipids Health Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2014.09.015","article-title":"CerS2 haploinsufficiency inhibits \u03b2-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance","volume":"20","author":"Raichur","year":"2014","journal-title":"Cell Metab"},{"key":"B64","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fendo.2019.00665\/full","article-title":"Inhibiting ceramide synthesis attenuates hepatic steatosis and fibrosis in rats with non-alcoholic fatty liver disease","author":"Jiang","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B65","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12944-019-1118-0","article-title":"Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis","volume":"18","author":"Yang","year":"2019","journal-title":"Lipids Health Dis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872\u2013034X.2011.00815.x","article-title":"Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels","volume":"41","author":"Promrat","year":"2011","journal-title":"Hepatol Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P056002","article-title":"Biomarkers of NAFLD progression: a lipidomics approach to an epidemic","volume":"56","author":"Gorden","year":"2015","journal-title":"J Lipid Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.002","article-title":"Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease","volume":"64","author":"Luukkonen","year":"2016","journal-title":"J Hepatol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1318","article-title":"Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis","volume":"41","author":"Apostolopoulou","year":"2018","journal-title":"Diabetes Care"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00330.2020","article-title":"Dihydroceramides: their emerging physiological roles and functions in cancer and metabolic diseases","volume":"320","author":"Lachkar","year":"2021","journal-title":"Am J Physiology-Endocrinology Metab"},{"key":"B71","doi-asserted-by":"publisher","first-page":"159318","DOI":"10.1016\/j.bbalip.2023.159318","article-title":"Dihydrosphingolipids are associated with steatosis and increased fibrosis damage in non-alcoholic fatty liver disease","volume":"1868","author":"Babiy","year":"2023","journal-title":"Biochim Biophys Acta (BBA) - Mol Cell Biol Lipids"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.04.013","article-title":"Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis","volume":"75","author":"Ooi","year":"2021","journal-title":"J Hepatol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12944-018-0855-9","article-title":"Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease","volume":"17","author":"Wasilewska","year":"2018","journal-title":"Lipids Health Dis"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M103705200","article-title":"Ganglioside GM3 participates in the pathological conditions of insulin resistance","volume":"277","author":"Tagami","year":"2002","journal-title":"J Biol Chem"},{"key":"B75","doi-asserted-by":"publisher","first-page":"109959","DOI":"10.1016\/j.cellsig.2021.109959","article-title":"Sphingosine 1-phosphate metabolism and insulin signaling","volume":"82","author":"Wigger","year":"2021","journal-title":"Cell Signal"},{"key":"B76","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1210\/er.2007-0025","article-title":"Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism","volume":"29","author":"Holland","year":"2008","journal-title":"Endocr Rev"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2021.06.006","article-title":"Sphingolipids in metabolic disease: The good, the bad, and the unknown","volume":"33","author":"Green","year":"2021","journal-title":"Cell Metab"},{"key":"B78","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.3390\/jcm12113730","article-title":"Potential hepatic lipid markers associated with nonalcoholic steatohepatitis and fibrosis in morbid obesity patients","volume":"12","author":"Wu","year":"2023","journal-title":"J Clin Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.12997\/jla.2020.9.3.380","article-title":"Ceramide\/sphingomyelin rheostat regulated by sphingomyelin synthases and chronic diseases in murine models","volume":"9","author":"Taniguchi","year":"2020","journal-title":"J Lipid Atheroscler"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/980815","article-title":"Inhibition of ceramide de novo synthesis with myriocin affects lipid metabolism in the liver of rats with streptozotocin-induced type 1 diabetes","volume":"2014","author":"Kurek","year":"2014","journal-title":"BioMed Res Int"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1042\/CS20191028","article-title":"Myriocin and d -PDMP ameliorate atherosclerosis in ApoE\u2013\/\u2013 mice via reducing lipid uptake and vascular inflammation","volume":"134","author":"Yu","year":"2020","journal-title":"Clin Sci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1177\/11786388221082012","article-title":"Myriocin treatment reverses alcohol-induced alterations in polyunsaturated fatty acid-containing phospholipid expression in the liver","volume":"15","author":"Yalcin","year":"2022","journal-title":"Nutr Metab Insights"},{"key":"B83","doi-asserted-by":"publisher","first-page":"7273","DOI":"10.1038\/s41598-022-11219-3","article-title":"Cordyceps inhibits ceramide biosynthesis and improves insulin resistance and hepatic steatosis","volume":"12","author":"Li","year":"2022","journal-title":"Sci Rep"},{"key":"B84","doi-asserted-by":"publisher","first-page":"7766","DOI":"10.1038\/s41598-023-34676-w","article-title":"Ceramide present in cholangiocarcinoma-derived extracellular vesicle induces a pro-inflammatory state in monocytes","volume":"13","author":"Oliviero","year":"2023","journal-title":"Sci Rep"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00222.2016","article-title":"Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis","volume":"312","author":"Mauer","year":"2017","journal-title":"Am J Physiology-Gastrointestinal Liver Physiol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M093799","article-title":"FTY720\/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice","volume":"60","author":"Rohrbach","year":"2019","journal-title":"J Lipid Res"},{"key":"B87","doi-asserted-by":"publisher","first-page":"19716","DOI":"10.1038\/s41598-023-46011-4","article-title":"Effect of FTY720P on lipid accumulation in HEPG2 cells","volume":"13","author":"Rida","year":"2023","journal-title":"Sci Rep"},{"key":"B88","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1289\/ehp.01109s2291","article-title":"Fumonisin-induced hepatocarcinogenesis: mechanisms related to cancer initiation and promotion","volume":"109","author":"Gelderblom","year":"2001","journal-title":"Environ Health Perspect"},{"key":"B89","doi-asserted-by":"publisher","first-page":"164436","DOI":"10.1016\/j.scitotenv.2023.164436","article-title":"Obesity promotes fumonisin B1 hepatotoxicity","volume":"891","author":"Dopavogui","year":"2023","journal-title":"Sci Total Environ"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.2478\/aiht-2023-74-3648","article-title":"Protective effects of resveratrol against fumonisin B1-induced liver toxicity in mice","volume":"74","author":"Yal\u00e7\u0131n","year":"2023","journal-title":"Arch Ind Hygiene Toxicol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.molmet.2018.12.008","article-title":"The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach","volume":"21","author":"Raichur","year":"2019","journal-title":"Mol Metab"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00455.2011","article-title":"Imipramine blocks ethanol-induced ASMase activation, ceramide generation, and PP2A activation, and ameliorates hepatic steatosis in ethanol-fed mice","volume":"302","author":"Liangpunsakul","year":"2012","journal-title":"Am J Physiology-Gastrointestinal Liver Physiol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2017.03.002","article-title":"Acid sphingomyelinase deficiency in Western diet-fed mice protects against adipocyte hypertrophy and diet-induced liver steatosis","volume":"6","author":"Sydor","year":"2017","journal-title":"Mol Metab"},{"key":"B94","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1194\/jlr.RA120000682","article-title":"Characterization of the small molecule ARC39, a direct and specific inhibitor of acid sphingomyelinase in vitro","volume":"61","author":"Naser","year":"2020","journal-title":"J Lipid Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00181.2019","article-title":"Amitriptyline inhibits nonalcoholic steatohepatitis and atherosclerosis induced by high-fat diet and LPS through modulation of sphingolipid metabolism","volume":"318","author":"Lu","year":"2020","journal-title":"Am J Physiology-Endocrinology Metab"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.06.009","article-title":"ASMase regulates autophagy and lysosomal membrane permeabilization and its inhibition prevents early stage non-alcoholic steatohepatitis","volume":"61","author":"Fucho","year":"2014","journal-title":"J Hepatol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.2099","article-title":"Glycine-\u03b2-muricholic acid antagonizes the intestinal farnesoid X receptor\u2013ceramide axis and ameliorates NASH in mice","volume":"6","author":"Jiang","year":"2022","journal-title":"Hepatol Commun"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J Hepatol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1194\/jlr.M031427","article-title":"Fenretinide inhibited de novo ceramide synthesis and proinflammatory cytokines induced by Aggregatibacter actinomycetemcomitans","volume":"54","author":"Yu","year":"2013","journal-title":"J Lipid Res"},{"key":"B100","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1038\/s41598-023-30759-w","article-title":"Fenretinide inhibits obesity and fatty liver disease but induces Smpd3 to increase serum ceramides and worsen atherosclerosis in LDLR\u2013\/\u2013 mice","volume":"13","author":"Thompson","year":"2023","journal-title":"Sci Rep"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-017-1375-2","article-title":"Inhibitors of ceramide de novo biosynthesis rescue damages induced by cigarette smoke in airways epithelia","volume":"390","author":"Zulueta","year":"2017","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav3722","article-title":"Targeting a ceramide double bond improves insulin resistance and hepatic steatosis","volume":"365","author":"Chaurasia","year":"2019","journal-title":"Science"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajcnut.2023.03.024","article-title":"Replacement of dietary saturated with unsaturated fatty acids is associated with beneficial effects on lipidome metabolites: a secondary analysis of a randomized trial","volume":"117","author":"Sellem","year":"2023","journal-title":"Am J Clin Nutr"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.2c00693","article-title":"Lipidomics revealed alteration of the sphingolipid metabolism in the liver of nonalcoholic steatohepatitis mice treated with scoparone","volume":"7","author":"Song","year":"2022","journal-title":"ACS Omega"},{"key":"B105","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S1388-1981(03)00059-3","article-title":"Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism","volume":"1632","author":"Hanada","year":"2003","journal-title":"Biochim Biophys Acta (BBA) - Mol Cell Biol Lipids"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41429-020-0351-0","article-title":"Discovery of fingolimod based on the chemical modification of a natural product from the fungus, Isaria sinclairii","volume":"73","author":"Chiba","year":"2020","journal-title":"J Antibiot (Tokyo)"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-020-01908-3","article-title":"Fingolimod affects transcription of genes encoding enzymes of ceramide metabolism in animal model of alzheimer\u2019s disease","volume":"57","author":"J\u0119\u015bko","year":"2020","journal-title":"Mol Neurobiol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.06.043","article-title":"Roles for chemokines in liver disease","volume":"147","author":"Marra","year":"2014","journal-title":"Gastroenterology"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000358","article-title":"A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia","volume":"27","author":"Enjeti","year":"2016","journal-title":"Anticancer Drugs"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.14744\/hf.2022.2022.0033","article-title":"Fingolimod induced fulminant liver failure requiring liver transplantation: A case report","volume":"4","author":"Caliskan","year":"2023","journal-title":"Hepatol Forum"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)98712-0","article-title":"Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with Fusarium moniliforme","volume":"266","author":"Wang","year":"1991","journal-title":"J Biol Chem"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-1981(02)00340-2","article-title":"Fumonisins and fumonisin analogs as inhibitors of ceramide synthase and inducers of apoptosis","volume":"1585","author":"Desai","year":"2002","journal-title":"Biochim Biophys Acta (BBA) - Mol Cell Biol Lipids"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.8b00188","article-title":"Mechanisms of fumonisin B1 toxicity: A computational perspective beyond the ceramide synthases inhibition","volume":"31","author":"Dellafiora","year":"2018","journal-title":"Chem Res Toxicol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00251.2013","article-title":"Acid sphingomyelinase plays a key role in palmitic acid-amplified inflammatory signaling triggered by lipopolysaccharide at low concentrations in macrophages","volume":"305","author":"Jin","year":"2013","journal-title":"Am J Physiology-Endocrinology Metab"},{"key":"B115","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3389\/fphys.2014.00331","article-title":"Inhibition of acid sphingomyelinase by tricyclic antidepressants and analogons","author":"Beckmann","year":"2014","journal-title":"Front Physiol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R115.653204","article-title":"Dihydroceramides: from bit players to lead actors","volume":"290","author":"Siddique","year":"2015","journal-title":"J Biol Chem"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.08.057","article-title":"An intestinal microbiota\u2013farnesoid X receptor axis modulates metabolic disease","volume":"151","author":"Gonzalez","year":"2016","journal-title":"Gastroenterology"},{"key":"B118","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1172\/JCI76738","article-title":"Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease","volume":"125","author":"Jiang","year":"2015","journal-title":"J Clin Invest"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024261","article-title":"Plasma ceramides, mediterranean diet, and incident cardiovascular disease in the PREDIMED trial (Prevenci\u00f3n con dieta mediterr\u00e1nea)","volume":"135","author":"Wang","year":"2017","journal-title":"Circulation"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.13329","article-title":"Efficacy of nutritional interventions to lower circulating ceramides in young adults: FRUVEDomic pilot study","volume":"5","author":"Mathews","year":"2017","journal-title":"Physiol Rep"},{"key":"B121","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.3390\/nu12113240","article-title":"Effects of a low dose of caffeine alone or as part of a green coffee extract, in a rat dietary model of lean non-alcoholic fatty liver disease without inflammation","volume":"12","author":"Vel\u00e1zquez","year":"2020","journal-title":"Nutrients"},{"key":"B122","doi-asserted-by":"publisher","first-page":"105170","DOI":"10.1016\/j.phrs.2020.105170","article-title":"Scoparone as a therapeutic drug in liver diseases: Pharmacology, pharmacokinetics and molecular mechanisms of action","volume":"160","author":"Hui","year":"2020","journal-title":"Pharmacol Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep"},{"key":"B124","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11892-020-01349-1","article-title":"Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease","volume":"20","author":"Budd","year":"2020","journal-title":"Curr Diabetes Rep"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/3920196","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Tanase","year":"2020","journal-title":"J Diabetes Res"},{"key":"B126","doi-asserted-by":"publisher","first-page":"7249","DOI":"10.1038\/s41598-018-25397-6","article-title":"The effect of high fat diet and metformin treatment on liver lipids accumulation and their impact on insulin action","volume":"8","author":"Zabielski","year":"2018","journal-title":"Sci Rep"},{"key":"B127","doi-asserted-by":"publisher","first-page":"102697","DOI":"10.1016\/j.ebiom.2020.102697","article-title":"Compounds that modulate AMPK activity and hepatic steatosis impact the biosynthesis of microRNAs required to maintain lipid homeostasis in hepatocytes","volume":"53","author":"Latorre","year":"2020","journal-title":"EBioMedicine"},{"key":"B128","doi-asserted-by":"publisher","first-page":"16033","DOI":"10.1038\/s41598-019-52263-w","article-title":"Metformin induces lipid changes on sphingolipid species and oxidized lipids in polycystic ovary syndrome women","volume":"9","author":"Pradas","year":"2019","journal-title":"Sci Rep"},{"key":"B129","doi-asserted-by":"publisher","first-page":"11478","DOI":"10.3390\/ijms231911478","article-title":"Lipids alterations associated with metformin in healthy subjects: an investigation using mass spectrometry shotgun approach","volume":"23","author":"Dahabiyeh","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B130","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.3390\/ijms22095016","article-title":"Metformin actions on the liver: protection mechanisms emerging in hepatocytes and immune cells against NASH-related HCC","volume":"22","author":"Zhang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00023.2018","article-title":"Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis","volume":"315","author":"Kalavalapalli","year":"2018","journal-title":"Am J Physiology-Endocrinology Metab"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.784391","article-title":"The insulin-sensitizer pioglitazone remodels adipose tissue phospholipids in humans","volume":"12","author":"Palavicini","year":"2021","journal-title":"Front Physiol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bcp.2015.03.010","article-title":"Impact of alogliptin and pioglitazone on lipid metabolism in islets of prediabetic and diabetic Zucker Diabetic Fatty rats","volume":"95","author":"Cai","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2662","article-title":"Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome","volume":"31","author":"Warshauer","year":"2015","journal-title":"Diabetes Metab Res Rev"},{"key":"B135","doi-asserted-by":"publisher","first-page":"100305","DOI":"10.1016\/j.jlr.2022.100305","article-title":"Rosiglitazone reverses inflammation in epididymal white adipose tissue in hormone-sensitive lipase-knockout mice","volume":"64","author":"Kotzbeck","year":"2023","journal-title":"J Lipid Res"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.2337\/db06-1065","article-title":"Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance","volume":"56","author":"Lessard","year":"2007","journal-title":"Diabetes"},{"key":"B137","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.trsl.2020.07.008","article-title":"The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet","volume":"227","author":"Somm","year":"2021","journal-title":"Trans Res"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021\u2013002395","article-title":"Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial","volume":"9","author":"Zobel","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B139","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12944-023-01922-z","article-title":"Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials","volume":"22","author":"Wretlind","year":"2023","journal-title":"Lipids Health Dis"},{"key":"B140","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12933-023-01845-0","article-title":"Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes","volume":"22","author":"Denimal","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1530\/JOE-19-0007","article-title":"Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis","volume":"241","author":"Kalavalapalli","year":"2019","journal-title":"J Endocrinol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41598-021-04361-x","article-title":"Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease","volume":"12","author":"Unsal","year":"2022","journal-title":"Sci Rep"},{"key":"B143","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.3390\/ijms23052883","article-title":"Effect of empagliflozin on sphingolipid catabolism in diabetic and hypertensive rats","volume":"23","author":"P\u00e9rez-Villavicencio","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0456","article-title":"Mechanisms of sodium\u2013glucose cotransporter 2 inhibition: insights from large-scale proteomics","volume":"43","author":"Ferrannini","year":"2020","journal-title":"Diabetes Care"},{"key":"B145","doi-asserted-by":"publisher","first-page":"6332","DOI":"10.3390\/ijms22126332","article-title":"Empagliflozin improves metabolic and hepatic outcomes in a non-diabetic obese biopsy-proven mouse model of advanced NASH","volume":"22","author":"Perakakis","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab722","article-title":"Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with type 2 diabetes","volume":"107","author":"Pirro","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1159\/000472966","article-title":"Influence of calcium content in mineral water on chemistry and crystallization conditions in urine of calcium stone formers","volume":"14","author":"Ackermann","year":"1988","journal-title":"Eur Urol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.603926","article-title":"Non-alcoholic steatohepatitis: A review of its mechanism, models and medical treatments","volume":"11","author":"Peng","year":"2020","journal-title":"Front Pharmacol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.3390\/diagnostics11112053","article-title":"Involvement of ceramides in non-alcoholic fatty liver disease (NAFLD) atherosclerosis (ATS) development: mechanisms and therapeutic targets","volume":"11","author":"Tanase","year":"2021","journal-title":"Diagnostics"},{"key":"B152","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.137474","article-title":"Acarbose has sex-dependent and -independent effects on age-related physical function, cardiac health, and lipid biology","volume":"5","author":"Herrera","year":"2020","journal-title":"JCI Insight"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0090","article-title":"Lipid profiling reveals different therapeutic effects of metformin and glipizide in patients with type 2 diabetes and coronary artery disease","volume":"37","author":"Zhang","year":"2014","journal-title":"Diabetes Care"},{"key":"B155","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12933-021-01431-2","article-title":"Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride","volume":"20","author":"Jendle","year":"2021","journal-title":"Cardiovasc Diabetol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1400961\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T01:14:49Z","timestamp":1718759689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1400961\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":155,"alternative-id":["10.3389\/fendo.2024.1400961"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1400961","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]},"article-number":"1400961"}}